多学科循证胸科ERAS项目实施后肺切除围术期结局
本前瞻性研究在学术四级医疗中心实施包含ERAS学会主要指南的胸科ERAS项目,评估295例择期肺切除患者的围术期结局。倾向评分匹配分析显示,项目实施后住院时间缩短1.2天、并发症减少12.0%、阿片类药物用量减少19口服吗啡当量/日、直接成本降低3500美元,再入院率无变化。这是ERAS学会胸科指南的首次外部验证。
要点
- 胸科ERAS项目实施后微创手术比例增加,ICU使用减少,术后第1天胸管和尿管拔除率提高。
- 倾向评分匹配显示住院时间缩短1.2天,并发症减少12.0%,阿片用量减少19口服吗啡当量/日。
- 尽管出院加快,再入院率保持稳定(6.3% vs 6.6%,P=0.94)。
核心结论
- 胸科ERAS项目可缩短肺切除患者住院时间、降低并发症、减少阿片类药物用量和直接成本,且不增加再入院率。
- 这是ERAS学会胸科指南的首次外部验证,其他中心采用可能获得类似获益。
研究设计与样本
- 前瞻性研究,纳入2015至2019年因肺部恶性肿瘤行择期肺切除的295例患者,ERAS实施前169例、实施后126例。
- ERAS项目包含ERAS学会所有主要指南,采用基于患者、肿瘤和手术特征的倾向评分匹配分析评估结局。
主要发现
- ERAS实施后微创手术比例从39.6%增至62.7%,ICU使用率从70.4%降至21.4%。
- 术后第1天胸管拔除率从24.3%增至54.8%,尿管拔除率从20.1%增至65.1%,术后第1天行走≥3次比例从46.8%增至54.8%。
- 倾向评分匹配分析(校正微创手术)显示住院时间缩短1.2天(95%CI 0.3-2.0;4.4→3.2)。
- 并发症减少12.0%(95%CI 1.6%-22.5%;32.0%→20.0%),阿片用量减少19口服吗啡当量/日(95%CI 1-36;101→82)。
- 手术和住院直接成本降低3500美元(95%CI 1100-5900;23000→19500),再入院率无变化(6.3%→6.6%;P=0.94)。
临床怎么用
- 在肺切除围术期推广包含ERAS学会主要指南的多学科胸科ERAS项目,以加速康复、减少并发症和阿片用量。
- 实施ERAS项目时需关注微创手术比例、早期拔管和早期活动等核心环节。
局限性
- 研究为单中心前瞻性前后对照设计,非随机对照试验。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This prospective study evaluated perioperative lung resection outcomes after implementation of a multidisciplinary, evidence-based Thoracic Enhanced Recovery After Surgery (ERAS) Program in an academic, quaternary-care center. BACKGROUND: ERAS programs have the potential to improve outcomes, but have not been widely utilized in thoracic surgery. METHODS: In all, 295 patients underwent elective lung resection for pulmonary malignancy from 2015 to 2019 PRE (n = 169) and POST (n = 126) implementation of an ERAS program containing all major ERAS Society guidelines. Propensity score-matched analysis, based upon patient, tumor, and surgical characteristics, was utilized to evaluate outcomes. RESULTS: After ERAS implementation, there was increased minimally invasive surgery (PRE 39.6%→POST 62.7%), reduced intensive care unit utilization (PRE 70.4%→POST 21.4%), improved chest tube (PRE 24.3%→POST 54.8%) and urinary catheter (PRE 20.1%→POST 65.1%) removal by postoperative day 1, and increased ambulation ≥3× on postoperative day 1 (PRE 46.8%→POST 54.8%). Propensity score-matched analysis that accounted for minimally invasive surgery demonstrated that program implementation reduced length of stay by 1.2 days [95% confidence interval (CI) 0.3-2.0; PRE 4.4→POST 3.2), morbidity by 12.0% (95% CI 1.6%-22.5%; PRE 32.0%→POST 20.0%), opioid use by 19 oral morphine equivalents daily (95% CI 1-36; PRE 101→POST 82), and the direct costs of surgery and hospitalization by $3500 (95% CI $1100-5900; PRE $23,000→POST $19,500). Despite expedited discharge, readmission remained unchanged (PRE 6.3%→POST 6.6%; P = 0.94). CONCLUSIONS: The Thoracic ERAS Program for lung resection reduced length of stay, morbidity, opioid use, and direct costs without change in readmission. This is the first external validation of the ERAS Society thoracic guidelines; adoption by other centers may show similar benefit.
引用
- Haro GJ, Sheu B, Marcus SG, et al. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program. Ann Surg. 2021. PMID: 31851005. doi:10.1097/SLA.0000000000003719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。